Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Image of the MS-UK Helpline button graphic containing a link to the Helpline page

Image of the New Pathways magazine button graphic containing a link to the New Pathways magazine page


The prevalence of trigeminal neuralgia in multiple sclerosis (MS) patients is higher than in the general population. Patients whose pain is insufficiently relieved by medication requires invasive...
Previous studies on caffeine and risk of multiple sclerosis (MS) yielded different results, with one study suggesting a positive effect on disease progression. In this study, researchers set out to...
Biopharmaceutical company Mapi Pharma will present two-year clinical data from its Phase II study of Glatiramer Acetate Depot for the treatment of relapsing remitting multiple sclerosis (RRMS) at the...
MPs and other policy makers should not let Brexit challenges draw attention and funding away from the chance to improve outcomes for everyone living with MS says Professor David Taylor from UCL...
A recent study has found that multiple sclerosis (MS) patients had significantly less fatigue on average after autologous hematopoietic stem cell transplantation (AHSCT). Fatigue is a common problem...
AIMS, the UK’s first charity with a focus on Haematopoietic Stem Cell Transplant (HSCT) for multiple sclerosis (MS) and autoimmune disease, is set to launch on the 24 November with a black tie gala...
A 10-year study of four multiple sclerosis (MS) disease modifying therapies (DMTs) -  Avonex, Rebif, Betaferon and Copaxone – has found them to be cost effective and successful at reducing disease...
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents, aged...
Headache is a common symptom in multiple sclerosis (MS), but not much is known about the cause of this particular symptom, which may or may not be MS related. A recent study investigated the...
A recent brief report by MS researchers at the Kessler Foundation has provided preliminary evidence that older individuals with multiple sclerosis (MS) report lower levels of depression and higher...

Pages

Live Chat Software by Click4Assistance UK